Continuous Infusion Of Hydrocortisone Reduces Hyperglyaemia In Patients With Septic Shock

Low dose hydrocortisone treatment is widely used as a treatment for patients suffering from septic shock. However, hydrocortisone stimulates glucose production in the liver and other tissues and may induce high blood glucose levels, or hyperglycaemia. Preventing hyperglycaemia has previously been shown to improve the survival of critically ill patients.

Pekka Loisa of the Päijät-Häme Hospital in Finland, and colleagues from hospitals throughout Finland carried out the trial involving 48 patients in four intensive care units (ICUs) between July 2005 and April 2006. One group of 24 patients received the hydrocortisone treatment by continuous infusion of 200mg/day. The bolus therapy group of 24 patients received the same overall dose, but the hydrocortisone was administered intravenously in 50mg doses every six hours. Loisa et al. compared blood glucose levels, insulin requirements and the nursing workload for the two groups. Hydrocortisone treatment lasted five days in both groups.

Loisa et al. found that the mean blood glucose levels were similar in both groups, but the number of hyperglycaemic episodes was higher in the group receiving bolus therapy. For patients undergoing bolus therapy, the insulin infusion rate had to be changed more often to maintain normal blood glucose levels, adding to nurses' workload. The researchers stress that normal blood glucose levels can be achieved successfully using both methods. However, strict normoglycemia is more easily achieved with continuous hydrocortisone infusion.

Article: Effect of hydrocortisone treatment modality on glycemic control in patients with septic shock. A prospective randomized trial Pekka Loisa, Ilkka Parviainen, Jyrki Tenhunen, Seppo Hovilehto and Esko Ruokonen Critical Care 2007 (in press)